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Abstract
Hepatic veno-occlusive disease (VOD), also known as 
sinusoidal obstruction syndrome, is a major complica-
tion of hematopoietic stem cell transplantation and it 
carries a high mortality. Prophylaxis for hepatic VOD is 
commonly given to transplant recipients from the start 
of conditioning through the early weeks of transplant. 
However, high quality evidence from randomized con-
trolled trials is scarce with small sample sizes and the 
trials yielded conflicting results. Although various treat-
ment options for hepatic VOD are available, most have 
not undergone stringent evaluation with randomized 
controlled trial and therefore it remains uncertain which 
treatment offers real benefit. It remains controversial 
whether VOD prophylaxis should be given, which pro-
phylactic therapy should be given, who should receive 
prophylaxis, and what treatment should be offered 
once VOD is established.
© 2012 Baishideng. All rights reserved.
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Hematopoietic stem cell transplantation (HSCT) is a 
standard therapeutic modality for many different malig-
nant and non-malignant diseases. However, complications 
from HSCT may result in severe morbidity and mortality. 
Major complications of  HSCT include hepatic veno-oc-
clusive disease (VOD), also known as hepatic sinusoidal 
obstruction syndrome. It is one of  the major causes of  
non-relapse, transplant-related mortality. Hepatic VOD 
can occur after autologous or allogeneic HSCT, regard-
less of  the underlying disease, stem cell source, or type 
of  pre-transplant conditioning. The incidence of  hepatic 
VOD after HSCT varies from 0 to 77%, depending on 
the risk of  the patient cohort; and the median incidence 
is 13.3%[1]. The mortality of  severe VOD is high at aver-
age of  84%[1]. Because of  its high incidence and mortal-
ity, prophylaxis for hepatic VOD is widely practiced, 
using different regimens in different centers. However, 
whether prophylaxis alters the occurrence of  VOD and 
which regimen is effective remains controversial. When 
hepatic VOD is established, specific therapy is usually 
given in addition to general supportive care, especially in 
moderate or severe cases. Different treatment strategies 
are tried with variable success, and no consensus regard-
ing standard treatment is currently available. We therefore 
briefly review the existing evidence base for prophylaxis 
and treatment of  hepatic VOD in this editorial and high-
light the uncertainties and deficiencies in the evidence.
Hepatic veno-occlusive disease after hematopoietic stem cell 
transplantation: Prophylaxis and treatment controversies
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DIAGNOSIS OF HEPATIC VOD
Diagnosis of  hepatic VOD is based on a constellation of  
symptoms and signs and serum bilirubin level. Hepatic 
VOD is clinically characterized by jaundice caused mainly 
by conjugated hyperbilirubinemia, tender hepatomegaly, 
fluid accumulation manifested as rapid weight gain and 
ascites. Most commonly used diagnostic criteria for 
VOD includes the Seattle criteria[2], the modified Seattle 
criteria[3], and the Baltimore criteria (also called Jones cri-
teria)[4]. Since different studies on prophylaxis and treat-
ment of  hepatic VOD might have used different criteria 
for diagnosis of  VOD, comparisons of  effectiveness of  
prophylaxis and treatment regimens across different stud-
ies may be difficult. 
The severity of  VOD is usually categorized into 3 
grades: mild, moderate, or severe, depending on adverse 
effect from VOD, treatment required, duration of  disease 
and mortality[3]. While mild hepatic VOD may resolve 
without specific therapy, severe VOD caries a high mor-
tality despite intensive therapeutic efforts. Because of  
variability and subjectivity in the definition of  disease 
severity and the distribution of  different severities within 
different cohorts of  patients, comparisons of  treatment 
results in different studies may be misleading.
PATHOGENESIS AND RISK FACTORS
The pathogenesis of  hepatic VOD is incompletely un-
derstood. The clinical manifestations of  hepatic VOD 
are thought to be caused by hepatic sinusoidal obstruc-
tion with or without occlusion of  intrahepatic central 
venules, resulting from dysfunction of  hepatic sinusoidal 
endothelial cells (SEC)[5,6]. The cause of  SEC dysfunction 
is multifactorial, and includes cytotoxic chemotherapy 
and radiotherapy, with concomitant glutathione and nitric 
oxide depletion, increased matrix metalloproteinases and 
vascular endothelial growth factor, and disturbances of  
inflammatory cytokines and coagulation and fibrinolytic 
system. Prophylaxis and treatment of  VOD therefore 
generally aims at preventing or relieving possible throm-
botic obstruction of  hepatic sinusoids and venules, or 
trying to prevent or restore the function of  SEC, replen-
ish anti-oxidants, promote vasodilation, and counter-
balance proinflammatory cytokines. 
Many different risk factors of  VOD have been de-
scribed, and they can be classified into patient factors, dis-
ease factors, and treatment factors (Table 1). Since many 
risk factors for hepatic VOD are not modifiable, prophy-
lactic therapy is commonly administered to selected high-
risk transplant recipients to prevent its occurrence. Some 
centers routinely give VOD prophylaxis to all transplant 
patients. However, the benefits and risks of  VOD pro-
phylaxis in different situations are not entirely clear. 
VOD PROPHYLAXIS
Prophylactic medications that have been used for he-
patic VOD with some success include heparin[7-10], low 
molecular weight heparin[11-13], danaparoid[14], ursodeoxy-
cholic acid[15,16], prostaglandin E1[10,17,18], glutamine[19], de-
fibrotide[20-25], and fresh frozen plasma (FFP)[7]. Some of  
these have also been tried in combination[7,13]. Prophylaxis 
is generally given continuously from the commencement 
of  conditioning till neutrophil engraftment or 1-3 mo 
after HSCT, during which hepatic VOD is most likely to 
develop. Some centers administer VOD prophylaxis to 
all patients who are undergoing HSCT while others only 
give prophylaxis to high risk patients, but the criteria for 
“high risk” is variable. High level evidence from random-
ized controlled trials supporting VOD prophylaxis is 
limited, and is only available for ursodeoxycholic acid, 
heparin, enoxaparin, glutamine, and FFP. They are briefly 
summarized below.
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Table 1  Risk factors of hepatic veno-occlusive disease
Risk factors Ref.
Patient factors
   Younger age in children [75-77]
   Older age in adults [78]
   Poor performance status [13,79,80]
   Glutathione S-transferase M1 null genotype [81]
   Hemochromatosis C282Y allele [82]
   Pre-existing hepatic dysfunction [2-4,79]
   Hypoalbuminemia [83]
   Hyperbilirubinemia [83]
   High serum ferritin [84]
   Positive CMV serology [85]
   Elevated plasma transforming growth factor β level [86]
   Hepatitis B or C infection [7,87-90]
   History of pancreatitis [85]
Disease factors
   Thalassemia major [76]
   Advanced malignancy [83,91]
   Acute leukemia [89]
   Neuroblastoma [75,77]
   Delayed platelet engraftment [75,76]
   Presence of acute graft-vs-host disease [83]
Treatment factors
   Interval between diagnosis and transplantation 
   greater than 13 mo
[83]
   Allogeneic HSCT [75,79]
   Unrelated donor HSCT [3,13,85,91]
   Mismatched donor [3,83]
   Second or subsequent transplants [7,84]
   Prior use of gemtuzumab ozogamicin [92]
   Prior use of norethisterone [93]
   Prior abdominal irradiation [3,7,77,79]
   Use of total parenteral nutrition within 30 d before 
   HSCT
[85]
   High dose cytoreductive therapy [79]
   Conditioning regimen containing busulfan with or 
   without cyclophosphamide
[3,75,76,84,85]
   Conditioning regimen containing fludarabine [85]
   Conditioning regimen containing melphalan [94,95]
   Total body irradiation [83,84]
   Graft-vs-host disease prophylaxis with 
   cyclosporin with or without methotrexate
[80,83,85]
   Use of sirolimus [96]
   Use of tranexamic acid [97]
   Platelet transfusion containing ABO-incompatible 
   plasma
[95]
HSCT: Hematopoietic stem cell transplantation.
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Ursodeoxycholic acid
There were 4 randomized controlled trials evaluating 
ursodeoxycholic acid for prophylaxis of  hepatic VOD 
in HSCT recipients. Their characteristics and results are 
summarized in Table 2. The first randomized controlled 
trial was the only double-blind, placebo-controlled trial[26]. 
Five of  35 patients (14.3%) who received ursodeoxycho-
lic acid compared with 13 of  32 patients (40.6%) who 
received placebo developed hepatic VOD, which was 
significantly different (RR 0.35, 95% CI: 0.14-0.88, P = 
0.02). Survival at Day+100 appeared higher in the urso-
deoxycholic acid group, but the difference was not sta-
tistically significant (77% vs 59%, P = 0.15). The second 
randomized controlled trial compared ursodeoxycholic 
acid with no ursodeoxycholic acid[27]. Two of  71 patients 
(2.8%) in the ursodeoxycholic acid group and 12 of  65 
patients (18.5%) in the control group developed hepatic 
VOD, which was significantly different (RR 0.15, 95% 
CI: 0.04-0.66, P = 0.01). None of  the patients in both 
groups died with hepatic VOD. The overall mortality was 
similar in both groups (21.1% vs 24.6%, RR 0.86, 95% 
CI: 0.46-1.59, P = 0.63). The third randomized controlled 
trial again compared ursodeoxycholic acid with no ur-
sodeoxycholic acid[28]. Three of  124 patients (2.4%) in 
the ursodeoxycholic acid group compared with 5 of  120 
patients (4.2%) in the control group developed hepatic 
VOD according to the Baltimore criteria, which was not 
significantly different (RR 0.58, 95% CI: 0.14-2.38, P = 
0.45). If  the Seattle criteria for VOD diagnosis were used, 
14 patients in each group developed hepatic VOD, again 
not significantly different between the 2 groups (RR 0.97, 
95% CI: 0.48-1.94, P = 0.93). Hyperbilirubinemia oc-
curred in 18 and 31 patients in the 2 groups respectively, 
which was significantly less frequent in patients who re-
ceived ursodeoxycholic acid (RR 0.56, 95% CI: 0.33-0.95, 
P = 0.03). There were 2 deaths related to hepatic VOD 
in the control group but none in the treatment group, but 
the difference was not statistically significant (RR 0.19, 
95% CI: 0.01-3.99, P = 0.29). The fourth trial compared 
ursodeoxycholic acid plus heparin with heparin alone[29]. 
Thirteen of  82 patients (15.9%) in the combined treat-
ment group compared with 16 of  83 patients (19.3%) 
in the heparin alone group developed hepatic VOD, 
which was not significantly different (RR 0.82, 95% CI: 
0.42-1.60, P = 0.56). There was also no significant differ-
ence in the frequency of  severe VOD (2.4% vs 6.0%, RR 
0.40, 95% CI: 0.08-2.03, P = 0.27). Survival at Day+100 
was also similar between the 2 groups (89.0% vs 89.2%).
Heparin
There were 2 open-label randomized controlled trials 
evaluating heparin for hepatic VOD prophylaxis. The 
first trial comparing low dose heparin infusion (1 mg/kg 
per day from Day 0 till discharge) with no heparin for 
VOD prophylaxis in autologous bone marrow trans-
plant recipients showed no significant difference in the 
incidence of  hepatic VOD between the 2 groups[9]. Four 
of  the 52 patients (7.7%) in the heparin group devel-
oped hepatic VOD and 1 of  the 46 patients (2.2%) in 
the control group had hepatic VOD (RR 3.54, 95% CI: 
0.41-30.53, P = 0.25). However, patients with increased 
risk to develop VOD were excluded from randomization 
and it was not clear what constituted “increased risk”. In 
contrast, the second trial comparing low dose heparin 
infusion (100 units/kg per day from Day-8 to Day+30) 
with no heparin in both allogeneic and autologous HSCT 
recipients showed a significantly lower incidence of  VOD 
in the heparin group[30]. Only 2 of  81 patients (2.5%) in 
the treatment group developed hepatic VOD, which was 
significantly less frequent compared to the control group, 
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Table 2  Randomized controlled trials of ursodeoxycholic acid for hepatic veno-occlusive disease
Trial reference Essell et al [26] 1998 Ohashi et al [27] 2000 Ruutu et al [28] 2002 Park et al [29] 2002
Blinding Double-blind Non-blind Non-blind Non-blind
Type of transplants Allogeneic Allogeneic or autologous Allogeneic Allogeneic or autologous
Donor Related Variable Variable NA
Stem cell source Bone marrow NA Variable NA
Conditioning Busulfan and cyclophosphamide 
or busulfan alone
Variable Variable Variable
No. of patients 
(treatment vs control)
35 vs 32 71 vs 65 124 vs 120 82 vs 83
Treatment regimen Ursodeoxycholic acid 300 mg 
BD (< 90 kg) or 300/600 mg 
BD (> 90 kg), given before 
conditioning till Day+80
Ursodeoxycholic acid 600 mg 
daily, given from Day-21 till 
Day+80
Ursodeoxycholic acid 
6 mg/kg per day BD, 
given 1 d before 
conditioning till Day+90
Ursodeoxycholic acid 300 mg 
BD, heparin 5 units/kg per 
hour, given 12-24 h before 
conditioning till Day+30
Control Placebo No drug No drug Heparin alone
Age of patients (yr, 
treatment vs control)
Mean 38 (22-56) vs 37 (21-56) Mean 34.5 vs 35.7 Median 38 (5-59) vs 
40 (1-58)
Median 39 vs 38
VOD criteria Seattle Seattle Baltimore, Seattle Modified Seattle
Frequency of VOD 
(treatment vs control)
14.3% vs 40.6% 2.8% vs 18.5% Baltimore 2.4% vs 4.2%; 
Seattle 11.3% vs 11.7%
15.9% vs 19.3%
Mortality at Day+100 
(treatment vs control)
22.9% vs 40.6% NA NA 11.0% vs 10.8%
NA: Data not available; VOD: Veno-occlusive disease.
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in which VOD occurred in 11 of  80 patients (13.7%) (RR 
0.18, 95% CI: 0.04-0.78, P = 0.02). Two patients in the 
heparin group and 7 patients in the control group died 
with VOD, which was not significantly different (RR 0.28, 
95% CI: 0.06-1.32, P = 0.11). On subgroup analysis, none 
of  the 39 patients (0%) who received heparin after al-
logeneic transplant developed hepatic VOD, but 7 of  the 
38 allogeneic transplant recipients (18.4%) who did not 
receive heparin had hepatic VOD, giving a relative risk of  
0.07 favoring the heparin group (95% CI: 0.00-1.10), with 
borderline statistical significance (P = 0.06). For autolo-
gous or syngeneic transplants, the difference between the 
2 groups was not significant, as 2 of  42 patients (4.8%) 
in the heparin group and 4 of  42 patients (9.5%) in the 
control group developed hepatic VOD (RR 0.50, 95% 
CI: 0.10-2.58, P = 0.1).
Low molecular weight heparin
There was one double-blind randomized controlled trial 
assessing the efficacy of  enoxaparin for prevention of  
hepatic VOD in allogeneic and autologous bone mar-
row transplant recipients above 15 years of  age[31]. Sixty-
one patients were randomized to receive enoxaparin 
40 mg daily by subcutaneous injection from 1 d before 
conditioning till Day+40 (28 patients) or placebo (33 pa-
tients). The incidence of  hepatic VOD was not reported 
in this study. However, it was found that 23 patients 
(82.1%) in the enoxaparin group and 28 patients (84.8%) 
in the control group had hyperbilirubinemia (RR 0.97, 
95% CI: 0.77-1.21, P = 0.78); 17 patients (60.7%) in the 
enoxaparin group and 27 patients (81.8%) in the control 
group had hepatomegaly (RR 0.74, 95% CI: 0.53-1.04, P 
= 0.08); 6 patients (21.4%) in the enoxaparin group and 
13 patients (39.4%) in the control group had right upper 
quadrant abdominal pain (RR 0.54, 95% CI: 0.24-1.24, P 
= 0.15); 20 patients (71.4%) in the enoxaparin group and 
21 patients (63.6%) in the control group had weight gain 
(RR 1.12, 95% CI: 0.79-1.59, P = 0.52); and 2 patients 
(7.1%) in the enoxaparin group and 2 patients (6.1%) in 
the control group had ascites (RR 0.59, 95% CI: 0.12-2.98, 
P = 0.52). None of  these outcomes were significantly 
different between the 2 groups. However, the duration of  
hyperbilirubinemia and hepatomegaly appeared shorter 
in the enoxaparin group compared to the control group 
(mean 7.4 d vs 15.3 d, P = 0.008; and mean 2.4 d vs 5.5 d, 
P = 0.03, respectively). All patients in this study survived.
Glutamine
There was one double-blind randomized controlled trial 
that compared glutamine with isonitrogenous amino acid 
mixture for protection of  hepatic function in allogeneic 
or autologous bone marrow transplant recipients[19]. 
Eighteen patients received daily infusion of  50 g gluta-
mine and 16 patients received daily infusion of  isonitrog-
enous amino acid mixture. Treatment was given from the 
start of  conditioning till discharge from the transplant 
unit. No hepatic VOD was observed in both groups of  
patients. One patient in the control group died from sep-
sis and acute graft-vs-host disease, while all patients in the 
glutamine group survived. There was no significant dif-
ference between the 2 groups in overall mortality (RR 0.3, 
95% CI: 0.01-6.84, P = 0.45). Of  note is that 4 patients 
in each group withdrew from treatment, among whom 
one was due to abdominal discomfort.
FFP
One open-label randomized controlled trial compared 
FFP infusion with no FFP for prophylaxis of  hepatic 
VOD in allogeneic HSCT recipients[32]. The patients were 
stratified into children and adults for randomization. Pa-
tients allocated to the FFP group (23 patients) received 
twice weekly FFP infusions from the start of  condition-
ing till Day+28 after HSCT and patients in the control 
group (20 patients) did not receive FFP. Hepatic VOD 
occurred in none of  the patients (0%) in the FFP group 
and 3 adult patients (15%) in the control group. The dif-
ference was not statistically significant (RR 0.13, 95% CI: 
0.01-2.28, P = 0.16). Mortality was not reported in this 
trial.
VOD TREATMENT
Fluid restriction, diuretics, and avoidance of  hepatotoxic 
medications are essential supportive care for patients who 
developed hepatic VOD. Specific therapeutic options on 
top of  these include tissue plasminogen activator[33-44], 
heparin[36], thrombomodulin[45], antithrombin Ⅲ[46-49], pro-
tein C[50], prostaglandin E1[51], glutamine[52,53], acetylcystei-
ne[54], methylprednisolone[55], and defibrotide[56-63]. Some 
of  the above have also been tried in combination[36,51,64-66]. 
Treatment is usually given until hepatic VOD resolves 
or the treatment is considered ineffective. In some cases, 
charcoal hemofiltration[67], transjugular intrahepatic por-
tosystemic shunt[68-71] or liver transplantation is performed 
as last resort[72,73]. However, little high level evidence on 
the treatment of  hepatic VOD exists and only one ran-
domized controlled trial is available which evaluated 2 
different doses of  defibrotide for treatment of  hepatic 
VOD.
This multicenter open-label randomized controlled 
trial compared defibrotide at 25 mg/kg per day (arm A, 
76 patients) with 40 mg/kg per day (arm B, 75 patients), 
both divided into 4 daily doses, given for at least 2 wk 
or until complete response[74]. Both pediatric and adult 
patients with either autologous or allogeneic HSCT were 
included. This trial found no significant difference in 
complete response rate between arms A and B (49% vs 
43%), survival at Day+100 (44% vs 39%), or treatment-
related adverse events (7% vs 10%).
SUMMARY OF EVIDENCE
High level evidence from randomized controlled trials 
supporting prophylaxis for hepatic VOD is scarce. Most 
trials were not double-blind and therefore susceptible to 
performance and assessment biases. The sample sizes 
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were also small, limiting generalizability of  results and 
the statistical power to make definitive conclusion. Urso-
deoxycholic acid might reduce the incidence of  hepatic 
VOD but trial results were conflicting. It is also uncertain 
which sub-group of  patients is more likely to benefit. 
Nevertheless, all trials failed to show any survival benefit 
in those who received ursodeoxycholic acid. Trial results 
on low dose heparin infusion for VOD prophylaxis were 
also conflicting, with 1 trial showing reduction of  VOD 
with heparin while the other trial showing no difference 
between the treatment and the control groups. It seemed 
that heparin was more likely to benefit allogeneic trans-
plant recipients as compared to autologous transplant 
recipients but there was insufficient statistical power to 
draw a more definitive conclusion. Similar to trials on 
ursodeoxycholic acid, both trials on heparin prophylaxis 
failed to show survival benefit. Trials on enoxaparin, 
glutamine and FFP all failed to demonstrate efficacy on 
reduction of  VOD or overall mortality when given pro-
phylactically. 
High level evidence on treatment options for hepatic 
VOD is even less. Only one randomized controlled trial 
was available. However, this trial just demonstrated that 
different doses of  defibrotide resulted in similar response 
rate and survival, without informing us whether defib-
rotide itself  was really effective or not. We are also un-
certain to what extents treatment benefits patients with 
different severities of  VOD. 
CONCLUSION
High quality clinical evidence on prophylaxis and treat-
ment of  hepatic VOD in hematopoietic stem cell trans-
plant recipients is scarce. Although anecdotal reports 
and some clinical trials suggested certain strategies may 
be effective for preventing and treating hepatic VOD, it 
remains controversial whether any of  these is indeed ef-
fective. It is also unclear who should receive prophylaxis 
and which treatment is most likely to offer the best risk-
benefit ratio. Large, double-blind, randomized controlled 
trials evaluating prophylactic and treatment options for 
hepatic VOD is therefore urgently needed.
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